Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double-blind, multi-center trial
Autore:
Heck, AH; Haffmans, PMJ; de Groot, IW; Hoencamp, E;
Indirizzi:
Psychiat Ctr Zon Schild, Amersfoort, Netherlands Psychiat Ctr Zon Schild Amersfoort Netherlands Amersfoort, Netherlands Stichting RBS, Den Haag, Netherlands Stichting RBS Den Haag NetherlandsStichting RBS, Den Haag, Netherlands
Titolo Testata:
SCHIZOPHRENIA RESEARCH
fascicolo: 2-3, volume: 46, anno: 2000,
pagine: 97 - 105
SICI:
0920-9964(200012)46:2-3<97:RVHIPP>2.0.ZU;2-T
Fonte:
ISI
Lingua:
ENG
Soggetto:
FIRST-EPISODE SCHIZOPHRENIA; MULTICENTER; PLACEBO;
Keywords:
antipsychotic; extrapyramidal symptom; haloperidol; risperidone; schizophrenia;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Life Sciences
Citazioni:
14
Recensione:
Indirizzi per estratti:
Indirizzo: Heck, AH Psychiat Ctr Zon Schild, Amersfoort, Netherlands Psychiat Ctr ZonSchild Amersfoort Netherlands rt, Netherlands
Citazione:
A.H. Heck et al., "Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double-blind, multi-center trial", SCHIZOPHR R, 46(2-3), 2000, pp. 97-105

Abstract

Background A randomized, double-blind, multi-center trial was started to compare the severity of extrapyramidal symptoms (EPS) during risperidone andhaloperidol treatment in schizophrenic patients who had disturbing EPS during their previous neuroleptic treatment. Additional objectives of this trial were comparing the antipsychotic effectiveness of the two treatments andthe use of antiparkinsonian medication. Methods. Effects of flexible doses of risperidone and haloperidol were compared in 77 psychotic patients (83% with chronic schizophrenia) with disturbing neuroleptic-induced EPS (risperidone 40 patients, haloperidol 37). Thetrial was completed by 47 patients: 25 in the risperidone: group (12 women, 13 men), and 22 in the haloperidol group (10 women, 12 men). Results. An adequate antipsychotic effect wits obtained in most patients by both treatments. The primary aim of this trial was comparing parkinsonismmeasured with the extrapyramidal syndrome rating scale (ESRS) during treatment with risperidone and haloperidol. Two primary parameters were selected: the change from baseline to the worst score during treatment of ESRS II (parkinsonism) and ESRS VI (clinical global impression of severity of parkinsonism), The CGI of severity of parkinsonism was better with risperidone (P= 0.025), while the parkinsonism total score tended to be better with risperidone (P<0.10). Before the double-blind treatment, 34 (of the 77) had used antiparkinson medication (risperidone 18, haloperidol 16). During the double-blind treatment phase, 21 patients had used antiparkinson medication (risperidone 11, haloperidol 10), The larger reduction of parkinsonism in therisperidone group was not due to a difference in the use of anti-parkinsonian medication. Conclusions. In this group of schizophrenic patients with disturbing EPS during previous neuroleptic treatment, a stronger reduction of parkinsonism was observed with risperidone than with haloperidol. (C) 2000 Elsevier Science B.V. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 31/05/20 alle ore 13:25:33